Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration Patients

Asfendiyarov Kazakh National Medical University

Status: Completed

Conditions: Age-Related Macular Degeneration

Treatments: Other: National Eye Institute Visual Function Questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT05427994

1394

Details and patient eligibility

About

The aim of this study is to evaluate the quality of life of AMD patients related to vision using the short version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), patients' social support, and their relationship with demographic and clinical variables.

Full description

Background and study aims. Age-related macular degeneration (AMD) is the most prevalent chronic progressive ocular disease. It has been shown in several studies that AMD affects the quality of life of patients. The aim of this study is to evaluate the quality of life of AMD patients related to vision using the short version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), patients' social support, and their relationship with demographic and clinical variables.

Who can participate? Patients with AMD, who wish to participate, will be recruited. Patients will be recruited from three locations of the Kazakh Scientific - Research Institute of Eye Diseases in Almaty, Nur-Sultan and Shymkent.

What does the study involve? The study involves collecting demographic data of the participants, collecting baseline visual testing data from medical records, filling out of the NEI-VFQ-25, and answering two yes/no questions related to the social support and reliability of social support.

What are possible benefits and risks of participating? Assessment of quality of life and social support of the AMD patients is a first step of developing targeted psycho-social support programs for AMD patients.

Where is the study run from? Patients will be recruited from three locations of the Kazakh Scientific - Research Institute of Eye Diseases in Almaty, Nur-Sultan and Shymkent.

When is the study starting and how long it is expected to run for? Start date 03/02/2020. End date 27/08/2022.

Who is funding the study? No funding for this study. Who is the main contact? Principal investigator: Inara Ismailova; [phone]; [e-mail]

Enrollment: 458 patients

Sex: All

Ages: 30 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age-related macular degeneration; ability to speak and understand Russian and/or Kazakh language; willingness to participate

Exclusion criteria

• Presence of glaucoma, cataracts of grade 2 or more according to the Lens Opacities Classification System (LOCS) III, and the presence of corneal opacities or any other retinal diseases

Trial design

458 participants in 1 patient group

Patients with age-related macular degeneration

Description:

Patients with age-related macular degeneration who fill out the quality of life questionnaire, and answer questions about social support and reliability of social support

Treatment:

Other: National Eye Institute Visual Function Questionnaire